Sonus Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
07 Mayo 2007 - 6:39PM
Business Wire
Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS), an oncology drug
development company, today announced that Michael A. Martino,
president and CEO, will present at the Acumen BioFin Rodman &
Renshaw 4th Global Healthcare Conference on Monday, May 14, 11:30
A.M. CEST (Central European Summer Time). The Company�s
presentation will be broadcast live at
www.sonuspharma.com/events.html. An archive of the call will be
available through the same link. About Sonus Pharmaceuticals
Located near Seattle, Washington, Sonus Pharmaceuticals, Inc. is
focused on the development of cancer drugs that are designed to
provide better efficacy, safety and tolerability, and are more
convenient to use. The Company�s lead product candidate, TOCOSOL�
Paclitaxel, is currently in a Phase 3 pivotal trial for the
potential treatment of metastatic breast cancer. Sonus expects
adjudicated data from the Phase 3 trial in the third quarter of
2007. Formulated with the Company�s proprietary TOCOSOL technology,
TOCOSOL Paclitaxel is an injectable, ready-to-use vitamin E-based
emulsion of paclitaxel that may reduce treatment-limiting side
effects and improve anti-tumor activity. In addition to the
continuing development of TOCOSOL Paclitaxel, Sonus initiated a
Phase 1 clinical trial for its second cancer drug, TOCOSOL
Camptothecin, in September 2006. For additional information on
Sonus, including past news releases, please visit
www.sonuspharma.com. Safe Harbor Certain statements made in this
press release are forward-looking such as those, among others,
relating to the development, safety and efficacy of therapeutic
drugs and potential applications for these products. As discussed
in Sonus Pharmaceuticals' filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for 2006 and
subsequent Quarterly Reports on Form 10-Q, actual results could
differ materially from those projected in the forward-looking
statements as a result of the following factors, among others:�the
Company's products will require extensive clinical testing and
approval by regulatory authorities; such approvals are lengthy and
expensive and may never occur; risks that the Company will not be
able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel;
risks that clinical studies with TOCOSOL Paclitaxel will be delayed
or will not be successful; risks that the FDA may not approve the
TOCOSOL Paclitaxel New Drug Application; risks that the Phase 1
clinical trial for TOCOSOL Camptothecin will not be successful;
risks of successful development of therapeutic drugs; and risks
that the Company may not be successful in obtaining funding from
third parties or completing a financing necessary to support the
costs and expenses of clinical studies as well as research and
development activities. The Company undertakes no obligation to
update the forward-looking statements contained herein or to
reflect events or circumstances occurring after the date hereof.
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sonus Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de Sonus Pharmaceuticals, Inc. Artículos de Noticias